Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma

Merryman, Reid W.; Rhoades, Justin; Xiong, Kan; Redd, Robert A.; Antel, Katherine; An, Hyun Hwan; McDonough, Mikaela; Guerrero, Liliana; Crnjac, Andela; Sridhar, Sainetra; Blewett, Timothy; Cheng, Ju; Dahi, Parastoo B.; Nieto, Yago; Joyce, Robin M.; Chen, Yi‐Bin; Herrera, Alex F.; Armand, Philippe; Murakami, Mark; Adalsteinsson, Viktor A.

doi:10.1002/hem3.47

HemaSphere

2024

DOI: 10.1002/hem3.47

|View full text |Cite

Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma

Reid W. Merryman,

Justin Rhoades,

Kan Xiong

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients

Krasnow,

Maurer,

Song

et al. 2024

Preprint

View full text Add to dashboard Cite

Despite responses of chimeric antigen receptor (CAR)-T cells in relapsed/refractory (R/R) large B cell lymphoma (LBCL) patients, over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify patients at high-risk of treatment failure. We recently developed MAESTRO, an ultrasensitive, tumor-informed measurable residual disease (MRD) assay, which can detect parts-per-million (ppm) levels of circulating tumor DNA (ctDNA) using minimal sequencing. We applied MAESTRO to 140 samples from 28 patients (15 durable responders at 12 months, 13 nonresponders) to identify treatment failure following axicabtagene ciloleucel (axi-cel) administered at our institution between 2018 and 2022. Responder and nonresponder patients had similar baseline tumor burden. By 1 week after infusion, responders had marked ctDNA reduction compared to nonresponders, p<0.001. At weeks 2 and 4, responders had ctDNA levels approaching 0 ppm, while nonresponders had persistence of ctDNA, each p<0.001. At day 0, 21% of patients had ctDNA fractions below 0.01%, hence these individuals would not have qualified for ctDNA monitoring with a less sensitive test. Our results confirm feasibility of highly sensitive MRD detection by ctDNA for early identification of patients at high risk of disease progression from axi-cel.

show abstract

Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients

Krasnow,

Maurer,

Song

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma

Cited by 1 publication

References 14 publications

Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients

Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients

Contact Info

Product

Resources

About